Jasper Bos, PhD, General Partner, will attend the 2026 SITC EU Immuno-Oncology Drug Development Summit, taking place 3–4 September in Lausanne, Switzerland.
Jasper will join the panel “Biotech Innovation in Europe and its Partnership with the US”, focusing on the European biotech funding landscape and the relationship between the European and US biotech ecosystems. He will be joined by leading European life sciences investors, including Francesco De Rubertis of Medicxi, Max Klement of Novo Holdings, Matthieu Coutet of Sofinnova Partners, and others, to discuss how investment and transatlantic collaboration can support biotech innovation and company building.
The summit brings together leaders from across the immuno-oncology ecosystem to discuss advances in drug development, translational science, clinical strategy, and the evolving landscape for innovative cancer therapies.